Treatment
During part A, participants were randomly (2:1) assigned to receive oral soticlestat or placebo (Dose selection was based on a comprehensive analysis of the safety, tolerability, pharmacokinetic, and pharmacodynamic data from single- and multiple-dose phase 1 studies in healthy volunteers [